Study to explore role of the Company’s anti-NRP2 antibodies in glioblastoma multiforme (GBM), the most common type of primary brain…
The collaboration aims to identify and develop accessible, minimally invasive blood-based biomarkers specific for tau pathology in the brainThese tools…
ANAVEX®2-73 corrects directly to humans’ translatable EEG biomarkers in a model of Fragile X Syndrome (FXS) Therapeutic potential to address…
LEXINGTON, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic…
– Completed enrollment in the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting; continued enrollment globally…
EIB offers Protembis venture debt for next-generation technology to reduce risk of brain injury in patients undergoing catheter-based heart treatment…
The esteemed annual symposium explores the most urgent questions facing our future BOSTON, July 29, 2024 /PRNewswire/ -- The Chopra…
New clinical data presented at world's largest forum for dementia research confirms BrainCheck Assess is as accurate as widely-used MoCA Refreshed…
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced the findings of a prospective study published in the Journal of Orthopaedics in…
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced the findings of a prospective study published in the Journal of Orthopaedics in…